会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 41. 发明授权
    • Benzaepinones as sodium channel blockers
    • Benzaepinones作为钠通道阻滞剂
    • US07888345B2
    • 2011-02-15
    • US12308209
    • 2007-06-05
    • Scott B. HoytClare LondonDong OkWilliam H. Parsons
    • Scott B. HoytClare LondonDong OkWilliam H. Parsons
    • C07D223/16A61K31/55A61P29/02
    • C07D223/16C07D401/12C07D403/12C07D409/12C07D413/12
    • Benzazepinone compounds represented by Formula (I), or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, urinary incontinence, pruritis, itchiness, allergic dermatitis, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier.
    • 由式(I)表示的苯并氮杂酮化合物或其药学上可接受的盐。 药物组合物包含单独的或与一种或多种其它治疗活性化合物组合的有效量的本发明化合物和药学上可接受的载体。 治疗与钠通道活性相关或由其引起的症状的方法,包括例如急性疼痛,慢性疼痛,内脏痛,炎性疼痛,神经性疼痛,癫痫,肠易激综合征,尿失禁,瘙痒,瘙痒,过敏性皮炎 抑郁,焦虑,多发性硬化和双相性精神障碍,包括单独施用有效量的本发明化合物或与一种或多种其它治疗活性化合物组合施用。 施用局部麻醉的方法包括单独施用有效量的本发明化合物或与一种或多种其它治疗活性化合物和药学上可接受的载体组合施用。
    • 49. 发明授权
    • Phosphorous containing dhp enzyme inhibitors
    • 含磷的dhp酶抑制剂
    • US5145990A
    • 1992-09-08
    • US642692
    • 1991-01-09
    • William H. ParsonsWilliam R. SchoenArthur A. Patchett
    • William H. ParsonsWilliam R. SchoenArthur A. Patchett
    • A61K31/40C07F9/30C07F9/58
    • C07F9/582A61K31/40C07F9/301C07F9/302C07F9/303C07F9/306
    • Compounds of the formula: ##STR1## wherein R.sub.1 is C.sub.2- C.sub.12 linear or branched unsubstituted alkyl; C.sub.1- C.sub.12 linear or branched substituted alkyl; C.sub.2 -C.sub.12 linear or branched monoalkenyl; C.sub.2 -C.sub.12 linear or branched alkynyl; C.sub.7 -C.sub.20 aralkyl, wherein the alkyl chain is linear or branched C.sub.1- C.sub.8 and the aryl moiety is C.sub.6- C.sub.12 ; C.sub.4- C.sub.10 cycloalkylalkyl; C.sub.3- C.sub.7 cycloalkyl; wherein these values for R.sub.1, other than C.sub.2- C.sub.12 linear or branched unsubstituted alkyl, can be substituted by one or more of C.sub.1 -C.sub.4 alkoxy, C.sub.3- C.sub.6 cycloalkyloxy, C.sub.3- C.sub.6 cycloalkylthio, C.sub.6- C.sub.12 aryloxy, C.sub.1- C.sub.4 alkylthio, C.sub.6- C.sub.12 arylthio, C.sub.7- C.sub.10 aralkyloxy, C.sub.7- C.sub.16 aralkyl-thio; and R.sub.5 is H or C.sub.1- C.sub.12 linear or branched alkyl; C.sub.2- C.sub.12 linear or branched monoalkenyl; C.sub.7- C.sub.20 aralkyl, wherein the alkyl chain is linear or branched C.sub.1- C.sub.8 and the aryl moiety is C.sub.6- C.sub.12 ; heterocyclic alkyl wherein the alkyl chain is linear or branched C.sub.1- C.sub.8 and the heterocyclic ring is 5-6 membered, optionally fused with a benzene ring, fully aromatic, containing 1 to 2 of oxygen, nitrogen or sulfur as heteroatoms; C.sub.4- C.sub.10 cycloalkylalkyl; C.sub.3- C.sub.7 cycloalkyl; wherein the values for R.sub.5 can be substituted by one or more of halo, hydroxy, carboxy, C.sub.1- C.sub.4 alkoxycarbonyl, C.sub.7- C.sub.16 arylalkoxycarbonyl, C.sub.3- C.sub.7 cycloalkyl, C.sub.1- C.sub.4 alkoxy, C.sub.6- C.sub.12 aryloxy, C.sub.3- C.sub.6 cycloalkyloxy, C.sub.3- C.sub.6 cycloalkylthio, amino, mono- or di- C.sub.1- C.sub.8 alkylamino, thio, C.sub.1- C.sub.4 alkylthio, C.sub.6- C.sub.12 arylthio, C.sub.7- C.sub.16 aralkylthio, or the radical --S--(CH.sub.2).sub.n CH(NH.sub.2)COOH. These compounds have dehydropeptidase (DHP) enzyme inhibitor activity.
    • 下式的化合物:其中R 1是C 2 -C 12直链或支链未取代的烷基; C1-C12直链或支链取代的烷基; C2-C12直链或支链单烯基; C2-C12直链或支链炔基; C 7 -C 20芳烷基,其中烷基链是直链或支链C 1 -C 8,芳基部分是C 6 -C 12; C4-C10环烷基烷基; C3-C7环烷基; 其中除了C 2 -C 12直链或支链未取代的烷基之外的R 1的这些值可以被一个或多个C 1 -C 4烷氧基,C 3 -C 6环烷氧基,C 3 -C 6环烷硫基,C 6 -C 12芳氧基,C 1 -C 4烷硫基, C6-C12芳硫基,C7-C10芳烷氧基,C7-C16芳烷硫基; R5为H或C1-C12直链或支链烷基; C2-C12直链或支链单烯基; C 7 -C 20芳烷基,其中烷基链是直链或支链C 1 -C 8,芳基部分是C 6 -C 12; 杂环烷基,其中烷基链是直链或支链C1-C8,杂环是5-6元,任选地与完全芳族的苯环稠合,含有1-2个氧,氮或硫作为杂原子; C4-C10环烷基烷基; C3-C7环烷基; 其中R 5的值可被卤素,羟基,羧基,C 1 -C 4烷氧基羰基,C 7 -C 16芳烷氧基羰基,C 3 -C 7环烷基,C 1 -C 4烷氧基,C 6 -C 12芳氧基,C 3 -C 6环烷氧基,C 3 -C 1-6环烷硫基,氨基,单或二-C 1 -C 8烷基氨基,硫代,C 1 -C 4烷硫基,C 6 -C 12芳硫基,C 7 -C 16芳烷硫基或基团-S-(CH 2)n CH(NH 2)COOH。 这些化合物具有脱氢肽酶(DHP)酶抑制剂活性。